Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients
Not yet recruiting
- Conditions
- Multiple Myeloma
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-30
- Target Recruit Count
- 159
- Registration Number
- NCT06933277
Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma
Phase 2
Not yet recruiting
- Conditions
- Multiple MyleomaMultiple Myeloma in RelapseMultiple Myeloma Refractory
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-03
- Target Recruit Count
- 52
- Registration Number
- NCT06880601
Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia
Phase 2
Not yet recruiting
- Conditions
- Acute Myeloid LeukemiaFLT3 Gene MutationAdult AMLDiagnosis
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-03-12
- Target Recruit Count
- 80
- Registration Number
- NCT06667973
HRQoL and Financial Toxicity in Patients with VEXAS Syndrome
Not yet recruiting
- Conditions
- VEXAS
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-10-26
- Target Recruit Count
- 100
- Registration Number
- NCT06657846
- Locations
- 🇮🇹
Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica, Ancona, Italy
🇮🇹Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia, Bergamo, Italy
🇮🇹Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia, Bologna, Italy
Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)
Not yet recruiting
- Conditions
- Acute Myeloid Leukemia, AdultAML, AdultAcute Myeloid Leukemia
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-07-22
- Target Recruit Count
- 397
- Registration Number
- NCT06513273
Observational Study on the Outcome of Patients With ITP Who Underwent Splenectomy After 2010
Not yet recruiting
- Conditions
- Primary Immune Thrombocytopenia
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-06-20
- Target Recruit Count
- 157
- Registration Number
- NCT06466824
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
Phase 2
Not yet recruiting
- Conditions
- CML, Chronic PhaseChronic Myeloid Leukemia, BCR/ABL-PositiveChronic Myeloid Leukemia, Chronic PhaseChronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-04-08
- Target Recruit Count
- 160
- Registration Number
- NCT06409936
Biological and Clinical Efficacy of Shingrix in Patients With CLL
Not Applicable
Not yet recruiting
- Conditions
- Chronic Lymphocytic LeukemiaCLL-like MBLSmall Lymphocytic LymphomaVaricella-zoster Virus Reactivation
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-05-09
- Target Recruit Count
- 312
- Registration Number
- NCT06364033
- Locations
- 🇮🇹
UOC Ematologia ASST dei Sette Laghi, Varese, Italy
Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program
Phase 2
Recruiting
- Conditions
- T-Lymphocytic Leukemia, Acute
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-11-08
- Target Recruit Count
- 31
- Registration Number
- NCT06253637
- Locations
- 🇮🇹
Ematologia AOU Careggi, Firenze, Italy
🇮🇹Ematologia P.O. Vito Fazzi - Lecce, Lecce, Italy
🇮🇹Ematologia AOU Policlinico Umberto I, Roma, Italy
Real-world Ruxolitinib Experience in PV
Not yet recruiting
- Conditions
- Polycythemia Vera
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-05-09
- Target Recruit Count
- 153
- Registration Number
- NCT06251102
© Copyright 2025. All Rights Reserved by MedPath